Hemorrhoid Treatment Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Hemorrhoid Treatment Devices Market Trends and Insights

Rising Prevalence of Hemorrhoidal Disease

Up to 50% of adults older than 50 experience symptomatic hemorrhoids, and growing life expectancy is pushing absolute case numbers higher. China alone is bracing for 1.4 million annual colorectal cancer cases by 2040; national screening rollouts mean more incidental hemorrhoid diagnoses that move quickly to procedural care.^{[3] J. Zheng et al., “Colorectal Cancer Projections in China,” The Lancet Oncology, thelancet.com} Similar screening acceleration is visible in India, Japan, and South Korea. The clinical community now favors earlier device intervention for Grades II-III to prevent progression, anchoring a long-term tailwind for the hemorrhoid treatment devices market.

Growing Adoption of Minimally Invasive Outpatient Procedures

Payers continue to steer patients away from inpatient excisional surgery toward office or ASC-based ligation. Medicare reimburses rubber band ligation (CPT 46221) at USD 158.85 per facility case in 2026, a level that supports high-volume practice economics. Vizient forecasts a 19% jump in total U.S. outpatient surgery between 2024 and 2034, with gastrointestinal work leading the rise. The convenience of 15-minute visits and same-day discharge aligns with patient preference, accelerating device throughput and revenue.

Technological Advances in Ligation and Energy Devices

Single-use bipolar probes, infrared coagulators, and reloadable clips continue to roll out with superior ergonomics and faster hemostasis. Olympus’ 2025 Retentia HemoClip and EZ Clip launches blended reusable and disposable strategies to accommodate divergent hospital budgets. Peer-reviewed trials report postoperative pain scores 30-40% lower with laser hemorrhoidoplasty than with conventional excision, supporting premium pricing and higher adoption of energy-based devices.

Expanding Healthcare Infrastructure in Emerging Economies

India’s pledge to lift public health spending to 2.5% of GDP by 2025 is translating into new endoscopy suites and subsidized colorectal screening. Similar budgets are visible in Indonesia, Vietnam, and Saudi Arabia. As middle-income hospitals secure financing, they are procuring mid-tier mechanical ligators first, then layering on energy platforms as procedure volumes climb. This gradual technology laddering broadens the total addressable base of the hemorrhoid treatment devices market.

High Cost of Stapling and Laser Systems

Capital outlays above USD 50,000 for a single laser console discourage adoption in resource-constrained hospitals despite clinical benefits. Deferred purchases are common in sub-Saharan Africa and lower-tier Chinese cities where budget committees favor mechanical ligators that cost one-tenth as much. Financing programs and leasing models are emerging, yet payback timelines stretch beyond five years for many facilities, slowing energy platform penetration.

Stringent FDA/CE Regulatory Pathways

Energy-based devices often require De Novo or pre-market approval, adding years and millions in test costs. Signum Surgical’s BioHealx cleared the FDA’s De Novo route only in mid-2024 after multiple clinical rounds, illustrating the hurdle for smaller innovators. While necessary for patient safety, these steps delay market entry and compress patent-protected sales windows.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Band Ligator Leadership, Laser Momentum

Band ligators owned 41.55% of 2025 revenue, underpinning the mechanical core of the hemorrhoid treatment devices market. High throughput, CPT-linked reimbursement, and a five-minute room turnaround keep demand brisk in physician offices and ASCs. The segment also benefits from infection-control upgrades as manufacturers roll out single-use variants. Laser probes, however, are set for a 9.01% CAGR, driven by compelling randomized evidence of superior pain relief and quicker return to work. Hospitals looking to differentiate colorectal programs are acquiring laser consoles, and private insurers in Germany and Japan now reimburse laser hemorrhoidoplasty, further lifting penetration.

By Technology Platform: Mechanical Base, Energy Upswing

Mechanical systems generated 53.74% of the hemorrhoid treatment devices market size in 2025 thanks to band ligator ubiquity and their minimal learning curve. Budget-sensitive public hospitals in Latin America and Africa still prioritize these platforms. Energy-based devices are catching up at an 8.92% CAGR, led by bipolar and infrared coagulators that eliminate costly endoscope reprocessing. ASCs in the U.S. often bundle a disposable probe into the procedure fee, easing capital constraints and smoothing the upgrade path for surgeons.

By Hemorrhoid Grade: II Dominant, IV Accelerating

Grade II treatments represented 39.62% of global volume in 2025, reflecting payers’ and clinicians’ preference for early outpatient management. The hemorrhoid treatment devices market share in Grade IV remains smaller but is expanding at an 8.01% CAGR as tertiary centers adopt Doppler-guided artery ligation and stapled hemorrhoidopexy for complex prolapse. Improved anesthesia protocols and faster discharge policies now allow many Grade IV cases to be scheduled in ASCs instead of inpatient ORs, broadening device demand.

By Procedure: Rubber Band First, Laser Fastest

Rubber band ligation dominated with 37.76% of 2025 procedures, and its cost advantage guarantees continued leadership. That said, laser therapy is rising on a 9.14% trajectory. Surgeons appreciate the bloodless field and reduced postoperative edema, and patients favor the short recovery window. Doppler-guided artery ligation and stapled hemorrhoidopexy fill more specialized niches, typically reserved for recurrent or circumferential prolapse.

By End User: Hospital Core, ASC Growth Track

Hospitals held 46.51% of 2025 spending, anchored by complex Grade III-IV caseloads and in-house anesthesia teams. Still, the hemorrhoid treatment devices market size captured by ASCs is climbing quickly at 8.33% CAGR as payers shift authorizations toward same-day settings. Physician offices remain the workhorse for single-ligator visits, especially in North America, while home-care use of disposable anoscopes is embryonic but gathering interest from tele-health startups.

Geography Analysis

North America generated 33.43% of 2025 revenue, underpinned by 6,300 Medicare-certified ASCs and clear procedural reimbursement. FDA device-intensive policies continue to influence purchasing, and infection-control rules make single-use ligators standard in many U.S. hospitals. Canada shows similar patterns, though provincial budgets extend capital cycles by one to two years longer than U.S. averages.

Asia-Pacific is the fastest-growing arena at 8.43% CAGR through 2031. China is scaling colorectal screening, and provincial insurance now covers laser hemorrhoidoplasty in several pilot provinces. India’s private hospital chains are opening dedicated day-surgery wings, equipping them with bipolar and infrared platforms to differentiate from public facilities. Southeast Asian markets such as Indonesia are piggybacking on endoscopy infrastructure funded for gastric cancer programs, creating incremental device demand.

Europe represents a mature but technology-hungry region. Germany and France reimburse energy-based procedures at higher tariffs than mechanical ligation, encouraging steady console refresh cycles every five to seven years. The United Kingdom is channeling National Health Service capital toward infection-risk reduction, pushing single-use devices to the fore. In Southern Europe, lingering budget limits lengthen adoption timelines, though EU-wide infection directives are narrowing the gap.

The Middle East & Africa and South America together account for a modest share but are important long-run contributors. Gulf Cooperation Council hospitals have moved rapidly into Doppler-guided and laser techniques to attract medical tourists, while Brazil and Colombia are expanding public coverage of outpatient ligation. Persistent shortages of colorectal surgeons and capital constraints temper growth, yet tele-endoscopy pilots and private specialty clinics are beginning to unlock latent demand.

Regulatory Landscape

Hemorrhoid treatment devices generally fall under established medical-device frameworks, with requirements varying by product and technology. In the United States, hemorrhoidal ligators are regulated as Class II devices under 21 CFR 876.4400, and some configurations may be 510(k)-exempt under defined limitations. Higher-risk energy-based systems and novel mechanisms can face more demanding FDA evidentiary pathways, including De Novo in certain cases, as seen with Signum Surgical's BioHealx clearance in mid-2024. Reimbursement-linked coding also affects market access in practice settings, with office and ASC throughput supported by Medicare payment for rubber band ligation (CPT 46221) at USD 158.85 per facility case in 2026.

In Europe, hemorrhoid devices must comply with Regulation (EU) 2017/745 (EU MDR), requiring clinical evaluation, post-market surveillance, and conformity assessment. Notified-body capacity and documentation burden continue to influence launch timing and portfolio prioritization, particularly for energy-based devices and stapling systems. The European Commission's device borderline and classification guidance remains an anchor for positioning anorectal accessories and treatment devices under MDR definitions, and manufacturers increasingly pair product rollouts with real-world data collection processes to support ongoing compliance.

Value Chain Analysis

The value chain starts with specialized component inputs (medical-grade polymers, elastomers, and metals for ligators, clips, staplers, and single-use probes) and extends through OEM manufacturing, sterilization and packaging, regulatory release, and commercialization via hospital and ambulatory channels. Mechanical ligation products typically depend on high-volume, cost-optimized manufacturing with strong distributor coverage, while energy-based platforms add capital equipment sourcing, service, and consumables management, often bundled into procedure economics in ASCs. Regulatory milestones act as inflection points that unlock downstream activity, illustrated by FDA 510(k) clearance for Ovesco Endoscopy AG's OTSCneo System Set in November 2025 and Cook Medical's CE Mark in March 2024 for a new hemorrhoid ligation device intended for EU commercialization.

Distribution and fulfillment differ by customer type: diversified medtech players use direct sales and group purchasing relationships for hospitals, while niche systems more often rely on direct-to-clinic models and focused channel partners for office-based procedures. Supply continuity and single-use conversion increasingly depend on contract manufacturing and molding partners for disposables, as reflected in Redfield Corporation's planned July 2026 delivery schedule for disposable slotted anoscopes manufactured with Monarch Molding to support the IRC2100 system. On the demand side, ASCs and physician offices influence product configuration choices (single-use kits, rapid setup, minimal reprocessing), while hospitals drive requirements for broader portfolio compatibility, service coverage, and infection-control documentation.

Market Opportunities and Future Outlook

Opportunities center on accelerating the shift of Grade II-III care into office and ASC settings and expanding higher-value energy and minimally invasive options when clinical differentiation is clear. The installed base of band ligators creates a conversion funnel to single-use, infection-control-forward kits and to premium energy-based modalities, supported by clinical evidence of lower postoperative pain for laser hemorrhoidoplasty and by payer dynamics that favor short visits and same-day discharge. In 2026, product releases reinforce this direction, including Triangel Medical's March 2026 Endolaser V6 dual-wavelength diode laser system positioned for proctology applications, adding to the competitive set of laser consoles and consumables that hospitals and ASCs evaluate when differentiating colorectal programs.

White space also extends to newer procedural pathways for bleeding-predominant or complex cases and to standardization of outcomes that helps providers and payers compare non-excisional interventions. Early clinical momentum for haemorrhoidal artery embolization (HAE) was reflected in the HEMBO-1 trial results presented at GEST 2026, pointing to incremental device and consumable demand across interventional radiology and colorectal care. In parallel, the steady cadence of Class II clearances, such as Ovesco Endoscopy AG's November 2025 FDA 510(k) clearance for OTSCneo as a hemorrhoidal ligator, supports ongoing room for iterative device upgrades, ergonomic improvements, and kit-based offerings that reduce procedure time and simplify adoption in outpatient workflows.